Cystic Fibrosis Clinical Trials

179 recruitingLast updated: June 17, 2026

There are 179 actively recruiting cystic fibrosis clinical trials across 26 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 4, Phase 3, Early Phase 1. Top locations include Boston, Massachusetts, United States, Birmingham, Alabama, United States, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Cystic Fibrosis Trials at a Glance

179 actively recruiting trials for cystic fibrosis are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Not Applicable with 32 trials, with the heaviest enrollment activity in Boston, Birmingham, and Philadelphia. Lead sponsors running cystic fibrosis studies include Vertex Pharmaceuticals Incorporated, Hospices Civils de Lyon, and Children's Hospital Medical Center, Cincinnati.

Browse cystic fibrosis trials by phase

Treatments under study

About Cystic Fibrosis Clinical Trials

Looking for clinical trials for Cystic Fibrosis? There are currently 158 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cystic Fibrosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cystic Fibrosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 179 trials

Recruiting

A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE

Non-cystic Fibrosis Bronchiectasis
AstraZeneca320 enrolled38 locationsNCT07245407
Recruiting

Role of Genetic Factors in the Development of Lung Disease

AsthmaCystic FibrosisPulmonary Fibrosis+2 more
National Heart, Lung, and Blood Institute (NHLBI)3,500 enrolled2 locationsNCT00001532
Recruiting
Phase 2

A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

Non-cystic Fibrosis Bronchiectasis
Sanofi70 enrolled3 locationsNCT07547436
Recruiting
Phase 2

Phase 2 Study to Assess the Safety and Efficacy of ANG003

Cystic Fibrosis (CF)Exocrine Pancreatic Insufficiency (EPI)
Anagram Therapeutics, Inc.113 enrolled26 locationsNCT07450547
Recruiting
Not Applicable

Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

Non-cystic Fibrosis Bronchiectasis
Physio-Assist622 enrolled57 locationsNCT06487273
Recruiting
Phase 1

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

Chronic Obstructive Pulmonary DiseaseNon-cystic Fibrosis Bronchiectasis
Genentech, Inc.128 enrolled7 locationsNCT06603246
Recruiting

Pharmacokinetics of Antibiotics in Patients With Cystic Fibrosis Trated With Elexacaftor/Tezacaftor/Ivacaftor (ETI)

Cystic Fibrosis (CF)Pulmonary ExacerbationRespiratory Infection Bacterial
Fondation Ildys30 enrolled1 locationNCT07629986
Recruiting
Not Applicable

FEED-Cystic Fibrosis (FEED-CF)

Cystic FibrosisCystic Fibrosis-related Diabetes
Emory University60 enrolled1 locationNCT05766774
Recruiting
Phase 4

Ensuring Access to Optimal Therapy in CF: The ENACT Study

Cystic Fibrosis (CF)
Arkansas Children's Hospital Research Institute100 enrolled3 locationsNCT07148739
Recruiting

Natural History of Noncirrhotic Portal Hypertension

Cystic FibrosisTurner SyndromeImmunologic Deficiency Syndrome+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)400 enrolled1 locationNCT02417740
Recruiting

Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)

Cystic Fibrosis-related Diabetes
University of Alabama at Birmingham30 enrolled1 locationNCT07102043
Recruiting

Rare CFTR Mutation Cell Collection Protocol (RARE)

Cystic Fibrosis
George Solomon500 enrolled1 locationNCT03161808
Recruiting
Phase 3

A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

Non-cystic Fibrosis Bronchiectasis
Haisco Pharmaceutical Group Co., Ltd.669 enrolled1 locationNCT07616375
Recruiting

Correction of Nonsense Mutations in Cystic Fibrosis

Cystic Fibrosis
University Hospital, Lille85 enrolled8 locationsNCT03670472
Recruiting

BASE: Bronchiectasis Severity and Exacerbation Risk Study

BronchiectasisBronchiectasis with Acute ExacerbationNon-cystic Fibrosis Bronchiectasis
Assiut University750 enrolled1 locationNCT07599839
Recruiting

Bronchiectasis Phenotype Identification Model

BronchiectasisBronchiectasis with Acute ExacerbationNon-cystic Fibrosis Bronchiectasis
Assiut University750 enrolled1 locationNCT07599969
Recruiting

Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)

Cystic Fibrosis
Emory University90 enrolled2 locationsNCT04002882
Recruiting
Phase 1

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated128 enrolled1 locationNCT07283770
Recruiting

Trikafta Exercise Study in Cystic Fibrosis

Cystic FibrosisLung Diseases
University of British Columbia20 enrolled1 locationNCT05279040
Recruiting
Phase 2

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

Cystic FibrosisDiabetesPancreatic Insufficiency+1 more
University of Pennsylvania30 enrolled2 locationsNCT04731272